Which statement best describes IVIVC and its value in formulation development and regulatory submissions?

Which statement best describes IVIVC and its value in formulation development and regulatory submissions?

• A. A predictive in vitro-in vivo correlation between dissolution and in vivo exposure; helps forecast bioavailability and reduce clinical trials.
• B. A measurement of how quickly a drug dissolves in simulated gastric fluid.
• C. An in vivo assay to measure dissolution rate in humans.
• D. A method to assess intestinal permeability.

Answer: (B)

IVIVC, or in vitro–in vivo correlation, is a predictive link between how a drug dissolves in a laboratory dissolution test and how it appears in the body after administration. In formulation development, a strong IVIVC lets you forecast in vivo bioavailability from dissolution data, helping you choose formulations, set robust dissolution specifications, and understand how changes in the product might affect performance. In regulatory submissions, a validated IVIVC can support bioequivalence arguments or waivers in certain cases, potentially reducing or skipping some clinical studies and speeding the path to approval. Describing how quickly a drug dissolves in simulated gastric fluid is just dissolution testing, not the predictive link to in vivo exposure. An in vivo assay to measure dissolution rate in humans isn’t a standard approach; typically, in vivo data involve measuring plasma drug concentrations over time, not a direct dissolution rate in humans. Assessing intestinal permeability addresses absorption, not the dissolution-to-exposure relationship that IVIVC captures.

IVIVC, or in vitro–in vivo correlation, is a predictive link between how a drug dissolves in a laboratory dissolution test and how it appears in the body after administration. In formulation development, a strong IVIVC lets you forecast in vivo bioavailability from dissolution data, helping you choose formulations, set robust dissolution specifications, and understand how changes in the product might affect performance. In regulatory submissions, a validated IVIVC can support bioequivalence arguments or waivers in certain cases, potentially reducing or skipping some clinical studies and speeding the path to approval.

Describing how quickly a drug dissolves in simulated gastric fluid is just dissolution testing, not the predictive link to in vivo exposure. An in vivo assay to measure dissolution rate in humans isn’t a standard approach; typically, in vivo data involve measuring plasma drug concentrations over time, not a direct dissolution rate in humans. Assessing intestinal permeability addresses absorption, not the dissolution-to-exposure relationship that IVIVC captures.